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Abstract
Prevalence findings for 1995 of illicit drug use as well as DSM-IV abuse and
dependence are reported from a representative population sample of 3,021
respondents from Munich, Germany, aged 14–24 years. Results are based on
personal interviews using the M-Composite International Diagnostic Inter-
view (M-CIDI) with its DSM-IV diagnostic algorithms. Findings indicate that
more than 30% of the adolescents and young adults are or have been using one
or more illicit drugs at least once in their life. Men were slightly more likely to
ever use drugs and used them more frequently than women. Cannabinoids
were by far the most frequently used type of drug, followed by various stimu-
lating drugs and hallucinogens. There is also considerable polysubstance use
among 14- to 24-year-olds. Criteria for DSM-IV abuse without dependence
were met by 4.1% of all men and 1.8% of all women, a dependence syndrome
of any type of illicit drug was diagnosed in 2.5% of the men and 1.6% of the
women. Cumulative age of onset incidence analyses suggest that substance use
starts early, in about one-third before the age of 16 years and continues to rise
for most drugs throughout adolescence and young adulthood. Overall these
findings suggest that substance use and substance disorders are more prevalent
than suggested in most previous German studies.
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Introduction
A variety of questionnaire surveys conducted in repre-
sentative population samples in Germany since 1980 [1–
3] suggested that the prevalence of illicit drug use has been
The EDSP study is supported by the German Federal Ministry for
Research and Technology, project No. 01EB94056.
increasing not only during the 80s [1], but continues to
rise in the 90s [2]. There are, however, considerable varia-
tions in findings across regions and in particular consider-
ably different rates in West and former East Germany,
making overall estimates of the size of the drug problem
in Germany somehow questionable. Since 1990 the fre-
quency of respondents aged 18–59 reporting to have used
some type of illegal drug at least once in their life
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increased overall in West Germany from 18.4 to 21.8%
and in East Germany from a low of 1.1 to 7.1%. Focusing
on current rates, defined as percentage of respondents
having used illicit drugs within the past 12 months, the
increase in drug use rates becomes even more evident.
Current use estimates increased from 5.1 to 9.5% in West
Germany and from 0.8 to 3.5% in East Germany. These
changes indicate that (1) the gap between low East Ger-
man and high West German estimates is rapidly closing
[2], and (2) that at least West German illicit drug use rates
are slowly approaching the lifetime rates of 30–40% illicit
drug use, reported from the US [4, 5].
According to the most recent large-scale federal ques-
tionnaire survey [2] of more than 6,200 respondents in
West Germany, increasing drug use rates are especially
pronounced among young adults. About 25% of respon-
dents aged 18–29 years reported in 1995 having used at
least once an illicit drug, an increase of more than 30%
when compared to 1990. Fairly consistently over time
cannabinoids were found to be the most frequently used
type of drug [1], followed by various types of stimulants
and hallucinogens, which seem to have increased consid-
erably since 1990 [6]. In contrast to the high rates for can-
nabinoids, rates for opioids are quite low, with prevalence
estimates ranging between 1 and 2% of the total popula-
tion. Also, comparisons with earlier investigations sug-
gest, that the proportion among lifetime users reporting
regular and heavy use is also increasing [2, 7]. Unfortu-
nately, no such powerful data are available for adolescents
aged younger than 18 years, because since 1994 the regu-
lar surveys of the federal ministry have not included this
age group anymore [8–10].
Although these data provide essential information
about the size of the illicit drug use problem in Germany,
they have several limitations. Aside from methodological
restrictions, such as fair response rates of about 65% with
no adjustments being made for potential non-response
distortions and the relative lack of sophistication of the
statistical analyses, the almost exclusive use of mailed
questionnaires with no established psychometric proper-
ties should be mentioned. Mailed questionnaires have the
disadvantage that it is not possible to control properly
whether the randomly selected target person fills out the
questionnaire himself and in privacy, and most impor-
tantly, questionnaires do not allow a sufficiently reliable
and valid evaluation of the diagnostic status in terms of
clinically relevant diagnoses. Because of the more com-
plex structure of diagnostic criteria for abuse and depen-
dence according to international diagnostic classification
systems, such as ICD-10 and DSM-III-R/DSM-IV, and
the modest association of frequency of use and diagnostic
status, it is unlikely that any self-report scales can provide
the details required in diagnostic evaluations [12]. Thus,
beyond detailed quantity and frequency information,
stratified by age and sex as well as supplementary infor-
mation about psychosocial risk factors, motivational pat-
terns and self-reported consequences resulting from drug
use, these data do not allow the derivation of abuse and
dependence diagnoses. The literature review by Perkon-
igg et al. [3] further demonstrates that there are no other
data available from more recent clinical epidemiological
studies in Germany filling this important gap in knowl-
edge.
Consequently, as no information is available for Ger-
many as a whole or for specific regions, no estimates are
feasible that allow us to indicate what proportion of the
population suffers from abuse and dependence of specific
types of illicit drugs. Whereas the lack of data concerning
the prevalence of illicit substance disorders might not be
that critical for primary preventive actions, the lack of
reliable and valid estimates for clinically relevant sub-
stance-specific abuse and dependence symptoms and dis-
order is critical especially as far as health service planning
and resource allocation are concerned.
Aims
This paper is the third [6, 11] in a series of publications
providing detailed descriptive epidemiological informa-
tion about the use, abuse and dependence of illicit sub-
stances. In addition to previously reported findings, this
paper reports EDSP data about the prevalence of illicit
drug use, abuse and dependence according to the criteria
and diagnostic algorithms of DSM-IV in 3,021 subjects,
aged 14–24 years, focusing on polysubstance use and the
association of frequency of use with diagnostic status. It is
important to note that the following findings – unlike all
previous German surveys – are based on personal exami-
nations by trained interviewers using the M-Composite
International Diagnostic Interview (M-CIDI) [12], which
assesses quantity and frequency information along with
clinically diagnostic questions for onset, course, and
the presence of diagnostic criteria for DSM-IV abuse
and dependence. The following issues will be addressed:
(1) What is the substance-specific lifetime prevalence of
illicit drug use in adolescents and young adults? (2) How
frequently does multiple substance use occur in this popu-
lation? (3) What is the prevalence of substance use disor-
ders according to DSM-IV criteria and how are symptoms
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of abuse and dependence as well as disorders related to
the frequency of use? (4) Finally, age at onset, characteris-
tics of abuse and dependence symptoms will be explored
to identify how early and which types of substance-related
diagnostically relevant problems occur in 14- to 24-year-
olds. It should be mentioned that more detailed descrip-
tions concerning prescription drugs [13] and amphet-
amines [14] will be discussed more comprehensively else-
where.
Methods
Since a complete and detailed description of design, sample,
instruments, procedures and statistical methods of the EDSP is given
elsewhere [15], only a few remarks should be made here.
Sample
The data reported include all 3,021 subjects of the EDSP consti-
tuting a representative sample of 14- to 24-year-olds in the greater
Munich area, Germany. All prevalence estimates reported are
weighted to take into account the age-stratified sampling scheme as
well as to adjust for nonresponse. The standard errors for the preva-
lence rates are available on request.
Assessment of Illicit Drugs
In the initial screening part of the M-CIDI substance section that
starts with the assessment of prescription drug use [for a detailed
overview of the substance use sections of the M-CIDI see 12, 13], the
respondent is first shown a comprehensive list of eight types of sub-
stances along with the most frequent market and street names.
Whenever the respondent identifies a substance taken at least once in
life, he or she is asked to underline this substance on the list for fur-
ther assessment of quantity and frequency of consumption as well as
associated diagnostic problems. Because almost all interviews were
conducted in the subjects’ home, with the potential risk that someone
might be listening, subjects were free not to loudly mention the con-
sumed substances, but to underline the names and simply mention
the group of substances. Further it is also important to note that ques-
tions for illicit drug use were preceded by a commitment probe estab-
lishing whether the person is willing to discuss openly the use of these
substances with the interviewer. Less than 1% denied this question.
In these cases the section was not administered. In addition to the
suggested drugs from the list the respondent was free to add any other
substance. All names of substances mentioned were cross-checked by
experienced M-CIDI editors, to ensure that the substance was cor-
rectly assigned to the respective drug class (cannabinoids, amphet-
amines, hallucinogens etc).
Terminology
Throughout this paper ‘lifetime user’ refers to respondents having
acknowledged the use of at least one substance on at least one occa-
sion in their life. ‘Regular use’ is defined in the M-CIDI as having
used the substance more than 4 times. ‘Heavy use’ denotes cases with
a prolonged and at least twice per week consumption pattern. ‘Diag-
nostic criteria’ and ‘diagnostic symptoms or problems’ refer to the
four DSM-IV abuse and the seven DSM-IV dependence criteria
[16].
Results
Prevalence and Age at Onset of Lifetime Ever Use of
Illicit Drugs
34.9% of the population aged 14–24 years reported
having used at least one of the substances listed in table 1
at least once in their lifetime, with 17.6% reporting infre-
quent (2 to 4 times) and 17.3% regular use. Overall, men
reported slightly higher rates (39.7%) than women
(30.4%). Cannabis dominates this picture with 6.5% re-
porting a single use, 11% infrequent and 15.5% regular
use. The next two most frequently used types of sub-
stances were stimulants, either of the amphetamine type
(5.0%) or cocaine products (4.0%) and hallucinogens
(3.2%). Opioid use was acknowledged by 3.4%. It should
be noted that this estimation also includes prescription
drugs like codeine as well as methadone. Except for can-
nabis, cocaine and inhalants, there was no significant gen-
der difference. However, regular use of nearly all sub-
stances was about 1.1–3.7 times more likely to be reported
by men as compared to women.
Figure 1 indicates that throughout all ages there are
subjects who use cannabis for the first time. The cumula-
tive hazard curve starts to pick up after age of 13 years
with an almost equal number of new incident cases at
each age up to 24 years. About one-third of all lifetime
cannabis users report an onset of use prior to age 16,
another third after age 20. First use of almost all other
substances is considerably later, rarely occurring before
age 16. On a lower overall cumulative incidence level, a
similar steady increase of incident cases over the full age
of onset range can be seen for cocaine and hallucinogens,
but not for opioids and amphetamines.
Since the data in table 1 suggest considerable overlap
between the different classes of substances, table 2 sum-
marizes the prevalence of single substance and multiple
lifetime users by frequency of use. By comparing the top
row findings of ‘any use’ with the subsequent rows, only a
small proportion of polysubstance users can be identified
among respondents that have used the substance just
once. However, among the total of 17.3% lifetime regular
users, about 40% do report multiple substance use, with
3.8% of the subjects having used regularly substances of
two, 1.8% of three, and 2.1% of four and more of the eight
classes of drugs assessed. Regular multiple substance use
appears to occur more frequently in men (8.8%) than in
women (6.7%).
Cannabis
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Table 1. Lifetime prevalence (%) of use by substance, frequency of use and gender1, 2
Substances Frequency of use Total Men Women Odds 95% CI
Just once
2–4 times
5 times or more
Total
6.5
11.0
15.5
33.0
7.1
12.3
18.8
38.2
6.0
9.6
12.3
27.9
1.4*
1.5*
1.8*
1.03–1.86
1.19–1.90
1.46–2.19
Amphetamines Just once
2–4 times
5 times or more
Total
1.0
1.5
2.4
5.0
1.1
1.9
3.0
5.9
1.0
1.1
1.9
4.0
1.1
1.7
1.6
0.55–2.24
0.92–3.09
0.99–2.55
Sedatives/
Hypnotics/
Anxiolytics
Just once
2–4 times
5 times or more
Total
0.2
0.7
0.7
1.6
0.2
0.5
0.9
1.6
0.3
0.9
0.5
1.7
0.6
0.5
1.7
0.11–2.84
0.20–1.24
0.71–4.16
Opioids Just once
2–4 times
5 times or more
Total
0.8
1.1
1.5
3.4
0.6
1.0
1.6
3.1
1.0
1.3
1.4
3.6
0.6
0.8
1.1
0.25–1.37
0.39–1.54
0.62–2.02
Cocaine Just once
2–4 times
5 times or more
Total
1.4
1.4
1.2
4.0
2.0
1.2
1.8
5.0
0.9
1.6
0.6
3.1
2.4*
0.8
2.8*
1.25–4.60
0.42–1.43
1.34–5.88
Hallucinogens Just once
2–4 times
5 times or more
Total
1.1
0.7
1.4
3.2
1.3
0.9
2.0
4.2
1.0
0.4
0.8
2.2
1.3
2.1
2.5*
0.65–2.55
0.84–5.33
1.29–4.91
Inhalants Just once
2–4 times
5 times or more
Total
0.2
0.4
0.7
1.3
0.2
0.4
1.1
1.7
0.2
0.3
0.3
0.8
0.9
1.5
3.7*
0.19–4.39
0.44–5.06
1.33–10.5
Other Just once
2–4 times
5 times or more
Total
0.2
0.4
0.4
1.0
0.2
0.5
0.5
1.2
0.3
0.3
0.3
0.9
0.6
2.0
1.4
0.13–2.90
0.60–6.39
0.44–4.53
Any use Just once
2–4 times
5 times or more
Total
6.5
11.1
17.3
34.9
7.4
12.1
20.2
39.7
5.7
10.1
14.6
30.4
1.4*
1.5*
1.8*
1.03–1.85
1.17–1.87
1.46–2.18
* p ! 0.05.
1 Weighted data.
2 Illicit use of prescription drugs included.
Prevalence of DSM-IV Threshold and Subthreshold
Diagnoses of Substance Abuse or Dependence and
Heavy Use
Figure 2a, b reveals the prevalence of substance use
disorders for men and women for each specific substance.
Overall, 2.9% fulfilled criteria for DSM-IV abuse without
dependence and 2% for dependence (with and without
abuse). Thus, 4.9% of the population of adolescents and
young adults received a diagnosis. Men are 2.3 times
more likely to develop substance abuse (OR = 2.3; 95% CI
= 1.48–3.63, p ! 0.05), but only slightly more likely to
develop dependence (OR = 1.5; 95% CI = 0.9–2.5, NS).
Any use
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Fig. 1. Cumulative incidence of illicit substance use.
Table 2. Lifetime prevalence of multiple drug use1, 2
Total
n %
Men
n %
Women
n %
Just once
2–4 times
5 times or more
198
335
524
6.5
11.1
17.3
110
181
302
7.4
12.1
20.2
88
154
223
5.7
10.1
14.6
One substance
Just once
2–4 times
5 times or more
193
298
292
6.4
9.9
9.7
110
159
171
7.3
10.6
11.5
83
139
121
5.4
9.1
7.9
Two substances
Just once
2–4 times
5 times or more
5
32
114
0.2
1.1
3.8
1
20
59
0.0
1.3
4.0
4
12
54
0.3
0.8
3.6
Three substances
Just once
2–4 times
5 times or more
0
5
56
0.0
0.2
1.8
0
2
31
0.0
0.1
2.1
0
3
25
0.0
0.2
1.6
Four or more sub-
stances
Just once
2–4 times
5 times or more
0
0
63
0.0
0.0
2.1
0
0
40
0.0
0.0
2.7
0
0
23
0.0
0.0
1.5
1 Weighted data.
2 Illicit use of prescription drugs included.
Among men, abuse (3.8%) and dependence (2.0%) result-
ing from the use of cannabinoids are the most prevalent,
followed by abuse/dependence of stimulants (amphet-
amines: abuse 0.8%, dependence 0.5%; cocaine: abuse
0.5%, dependence: 0.5%), and hallucinogens (abuse:
0.5%, dependence: 0.3%).
In each substance class there are a considerable num-
ber of respondents that do report heavy regular use and at
least some diagnostic symptoms of abuse and dependence
without reaching the full DSM-IV diagnostic threshold
(subthreshold substance disorders). Figure 2c splits the
total number of lifetime ever users for each class of sub-
stances into those with heavy use without significant signs
of an abuse or dependence syndrome, those with subthre-
shold diagnoses and those meeting full diagnostic criteria
according to DSM-IV criteria. This picture suggests that a
considerable number of cases are quite close to getting a
diagnosis, especially among hallucinogen and amphet-
amine users. These two groups also reveal the lowest pro-
portion of heavy users without any signs of abuse or
dependence.
Patterns of Polysubstance Abuse and Dependence
Table 3 reveals considerable overlap between sub-
stance classes in terms of diagnoses of abuse and depen-
dence, suggesting considerable comorbidity between var-
ious classes of substance use disorders. Among those with
Cannabis
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Fig. 2. a Lifetime prevalence of DSM-IV abuse. b Lifetime prev-
alence of DSM-IV dependence. c Percent of lifetime users with
heavy use, subthreshold and threshold disorders.
Table 3. Lifetime substance use disorder comorbidity: pure and multiple substance use disorders 1
Substance use
disorders
n Cannabis
n %
Amphetamines
n %
Hallucinogens
n %
Cocaine
n %
Opioids
n %
Inhalants
n %
ASH2
n %
125 100 80 22 18 18 4.1 15 11.7 5 4 1 0.9 8 6
Amphetamines 25 22 88 0 0 19 76 14 56 5 20 1 4 6 24
Hallucinogens 19 18 94.7 19 100 0 0 9 47.4 2 10.5 1 5.3 4 21.1
Cocaine 19 15 78.9 14 73.7 9 47.4 4 21.1 6 31.6 1 5.3 5 26.3
Opioids 9 5 55.6 5 55.6 2 22.2 6 66.6 3 33.3 0 0 4 44.4
Inhalants 2 1 50 1 50 1 50 1 50 0 0 1 50 0 0
ASH 10 8 80 5 50 4 40 5 50 4 40 0 0 2 20
Values in boxes = Pure substance disorders.
1 Weighted data.
2 ASH = Anxiolytics/Sedatives/Hypnotics.
a b
c
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Fig. 3. Cumulative incidence of abuse symptoms for cannabis.
hallucinogen (n = 19) or amphetamine (n = 25) disorders,
not one single case was identified having just this disor-
der. Among amphetamine users, 88% also had a cannabis
diagnosis, 76% a hallucinogen disorder and 20% an
opioid disorder. Quite similar polysubstance comorbidity
is evident for those with cocaine and opiate disorders.
Cumulative Incidence of Diagnostic Symptoms and
Criteria for Abuse and Dependence Diagnoses
Figure 3 presents the cumulative hazards by age of first
onset for DSM-IV diagnostic criteria of abuse. Due to low
base rates for many of the substance classes this figure is
restricted to cannabinoids only. The DSM-IV criterion of
‘recurrent use in dangerous situations’ (driving, operating
machines, etc.) is the most frequently endorsed symptom
showing a fairly steep and steadily rising cumulative inci-
dence rate, starting after the age of 14 years. After the age
of 19 years the curve levels off slightly, suggesting that
after this age only few new cases with first onset of this
symptom are observed. The second most frequent criteri-
on refers to ‘recurrent social and interpersonal problems’
because of the cannabis use. There is a slightly later age of
onset for this symptom, with two high incident intervals,
namely at the age of 16–18 years and less clearly after the
age of 22 years. The remaining two DSM-IV symptoms,
including substance-related legal problems, occur mostly
between the age of 16 and 19 years for the first time. After
the age of 20 years the first occurrence of these symptoms
is rare.
Such cumulative incidence curves for dependence cri-
teria were also computed for DSM-IV dependence symp-
toms discussed elsewhere [11]. Compulsive use as well as
the development of tolerance are overall the most fre-
quently reported dependence symptoms in cannabis de-
pendence, with hazards for both increasing steadily after
the age of 14 years and peaking for tolerance at the age of
19–20 years as well as after the age of 23 years. The age at
first onset of DSM-IV criterion (7) ‘use despite knowledge
of having a recurrent psychological problem’ shows a
markedly different pattern, with peak incidence between
the age of 14 and 17 years and after the age of 23 years.
Discussion
To our knowledge this is the first study conducted in
Germany investigating the prevalence of use, abuse and
dependence on the basis of a personally administered diag-
nostic interview in a representative population sample.
Our findings have revealed that illicit substance use is
quite prevalent among adolescents and young adults, with
40% of the men and 30% of the women having tried some
drug at least once in their life. As compared to the 1995
questionnaire survey data [2] of 18- to 24-year-olds in
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West Germany, the EDSP rates assessed in the same year
are considerably higher, overall as well as for the specific
substance classes examined. It is hard to know to what
degree these differences are due to the different assess-
ment methodology used or simply reflect the different
sampling scheme (Germany versus metropolitan Mu-
nich). Irrespective of this, our findings indicate that the
prevalence of use in Munich is much higher than pre-
viously assumed in the vast majority of prior studies [1]
and resembles very much findings for the United States
[4]. It is remarkable that up to 40% of all drug users in our
sample reported having started using drugs before the age
of 14 years. In accordance with all previous studies, can-
nabinoids still dominate the drug scene, substance users
that have never tried cannabinoids being extremely rare.
However, there are also strong indications that halluci-
nogens and stimulating drugs, especially Ecstasy and
related substances as well as cocaine, are being consider-
ably more frequently used than the 1990, 1994 and 1995
federal surveys [2] have suggested. It is also noteworthy
that drug use rates for men and women were relatively
similar in our study.
Although we expected predominantly one time only
users in 14- to 24-year-olds, the majority of our popula-
tion has been using drugs regularly and almost one-third
could be described as heavy users. Also polysubstance use
is not rare with almost 40% of all users reporting the
intake of drugs from at least two substance classes. Partic-
ularly among stimulating drug users, the concurrent use of
hallucinogens and cannabis is quite frequent.
Given the examined age range of 14–24 years and con-
sidering that the most frequently used substance – canna-
bis – is usually rated as having a low dependence poten-
tial, the prevalence for full-blown DSM-IV substance dis-
orders of 4.9% could be called considerable. Overall, 4.1%
of the men and 1.8% of the women fulfilled criteria for
full-blown DSM-IV abuse and additionally 2.5% of the
men and 1.6% of the women met criteria for dependence.
Additionally, depending on the predominant type of sub-
stance used, 21–47% of all regular users were classified as
having subthreshold disorders without meeting full diag-
nostic criteria. The potential for developing abuse and
dependence as well as polysubstance disorders is especial-
ly pronounced for amphetamines, hallucinogens and co-
caine. In our population we could not identify any case
having a disorder of just one of these drug classes.
These prevalence findings are partly in contrast to the
few available German clinical epidemiological studies,
conducted in the 80s, which estimated very low drug dis-
order prevalence [1, see review in 17]. Our findings are,
however, quite similar to diagnostic rates reported from
the US, such as the slightly lower rates in the Epidemio-
logical Catchment Area study conducted in 1981 [18] and
the almost identical findings from the National Comor-
bidity Survey [19].
Use of illicit substances is a period-, age-, and develop-
ment-dependent phenomenon. Thus, cross-sectional
analyses of a fairly broad and, in terms of substance use
initiation and its progression to regular and heavy use,
critical age range, have the limitation of being only a pre-
liminary report. Such reports do not allow us to draw firm
conclusions about use and symptom progression into sub-
stance disorders, because such processes depend on many
factors, such as cognitive and behavioral developmental
and life style changes of an individual, the changing pat-
terns in the availability of drugs over time and more gen-
eral secular trends.
Thus, although one could assume that due to the find-
ing that even among 14- to 16-year-olds illicit substance
use is further on the rise with gradually further rising risks
for heavy use, abuse, and dependence this must not neces-
sarily be the case and therefore such cross-sectional find-
ings must be interpreted with caution. Longitudinal pro-
spective designs are needed to examine in more detail the
probabilities and associated risk factors of the transitions
from first use to regular use and from there to possibly
heavy use and the development of abuse and dependence
syndromes. However, at each of these developmental
stages spontaneous or treatment-related partial and com-
plete remissions, and discontinuation of substance use
respectively, might occur. In our ongoing second and
third follow-up investigations we are collecting such data
and hopefully will provide further insight into the mecha-
nisms of the early stages of illicit substance use disorders.
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